

- **Name:** Michael R. Bishop, MD, FACP, FASCO
 - **Current Position & Affiliation:** Professor of Medicine, Director, the David and Etta Jonas Center for Cellular Therapy, University of Chicago, Chicago, IL
 - **Country:** USA
-
- **Educational Background:**
 - 1985: M.D., University of Illinois College of Medicine, Chicago, Illinois
 - 1985 – 1988: Internship and Residency, Internal Medicine, Northwestern Memorial Hospital, Chicago, Illinois
 - 1988 – 1991: Fellowship, Hematology/Oncology, Loyola University Medical Center, Maywood, Illinois
 - **Professional Experience:**
 - 7/1997 - 2/1999: Associate Professor of Medicine, University of Nebraska Medical Center
 - 3/1999 – 5/2007: Investigator (Tenure Track), National Cancer Institute, National Institutes of Health
 - 6/2007 – 2/2011: Senior Investigator (Tenured), National Cancer Institute, National Institutes of Health
 - 4/2011 – 10/2012: Professor of Medicine
Head, Section of Adult Hematologic Malignancies, Medical College of Wisconsin
 - 11/2012 – present: Professor of Medicine
Director, the David and Etta Jonas Center for Cellular Therapy, University of Chicago
 - **Professional Organizations:**
 - Fellow, American Society of Clinical Oncology (ASCO)
 - Member, American Society of Hematology (ASH)
 - Member, American Society for Transplantation and Cellular Therapy (ASTCT)
 - Fellow, American College of Physicians
 - Member, European Society for Cancer Immunology and Immunotherapy
 - Member, Society for Immunotherapy of Cancer (SITC)
 - Member, Society of Hematologic Oncology (SOHO)
 - **Main Scientific Publications:**

1. Schuster SJ, **Bishop MR**, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med.* 80:45-56, 2019.
2. **Bishop MR**, Dickinson M, Purtil D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. *N Engl J Med.* 2022; 386:629-639.
3. Shah BD, Ghobadi A, Oluwole OO, Logan AC, Boissel N, Cassaday RD, Leguay T, **Bishop MR**, Topp MS, Tzachanis D, O'Dwyer KM, Arellano ML, Lin Y, Baer MR, Schiller GJ, Park JH, Subklewe M, Abedi M, Minnema MC, Wierda WG, DeAngelo DJ, Stiff P, Jeyakumar D, Feng C, Dong J, Shen T, Milletti F, Rossi JM, Vezan R, Masouleh BK, Houot R. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. *Lancet.* 2021; 398(10299):491-502.
4. Neelapu SS, Adkins S, Ansell SM, Brody J, Cairo MS, Friedberg JW, Kline JP, Levy R, Porter DL, van Besien K, Werner M, **Bishop MR**. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. *J Immunother Cancer.* 8:e001235, 2020.